Cargando…
Homozygous FCGR3A-158F mutation is associated with delayed B-cell depletion following rituximab but with preserved efficacy in a patient with refractory lupus nephritis
Rituximab (RTX), an anti-CD20 monoclonal antibody, has shown promising results in a small group of systemic lupus erythematosus (SLE) patients treated for lupus nephritis (LN). However, such observations were not confirmed in the double-blind LUNAR study. Accordingly, the factors associated with the...
Autores principales: | Seret, Guillaume, Hanrotel, Catherine, Bendaoud, Boutahar, Le Meur, Yannick, Renaudineau, Yves |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094396/ https://www.ncbi.nlm.nih.gov/pubmed/27818754 http://dx.doi.org/10.1093/ckj/sfs162 |
Ejemplares similares
-
Mesangial Cell-Specific Antibodies Are Central to the Pathogenesis of Lupus Nephritis
por: Seret, Guillaume, et al.
Publicado: (2012) -
Rituximab can Decrease Proteinuria in Refractory Lupus Nephritis
por: Suh, Chang-Hee
Publicado: (2022) -
17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia
por: Bagacean, Cristina, et al.
Publicado: (2019) -
Rituximab is effective in the treatment of nephritis in lupus patients, refractory to conventional immunosuppressive therapy
por: Martínez, R, et al.
Publicado: (2010) -
Rituximab for treatment of severe lupus nephritis
por: Baskin, E, et al.
Publicado: (2008)